INDIGO
Development of novel influenza vaccine in the EU, India, and United States
Objective
To collaborate with partners in the EU, India and in the United States on the development of two novel influenza vaccine concepts that meet the requirements of global vaccination. We aim to have a sub 10% non-response rate, lower costs, and improve accessibility.
Description
INDIGO project involves public and private R&D organisations in the EU, India and United States for the development of two influenza vaccine concepts. The first concept combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel adjuvant, aiming to obtain proof-of-concept in phase I and II trials within 5 years. The second concept is based on innovations including a recombinant viral hemagglutinin with increased immunogenicity, a potent adjuvant and needle-free delivery by intradermal patches. The plans are realistic with a high probability to deliver next-generation flu vaccines.
Partners
Lite Vax
Univ Gent
Universitair Ziekenhuis Gent
ExpreS2ion Biotechnologies
Stanipharm
Cellvax
Viroclinics Biosciences BV
Institut National de la Sante et de la Recherche Medicale
EpiVax
Transnational Health Science And Technology Institute
CBCI Society for Medical Education
Council of Scientific and Industrial Research
Christian Medical College Vellore
Gennova Biopharmaceuticals Limited
Clinical Development Services Agency
Funders
European Commission Horizon 2020
Countries
Netherlands, Belgium, France, Denmark, India, United States